National Institute for Health Research, School for Primary Care Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
Department of Primary Care and Public Health, Brighton and Sussex Medical School, University of Brighton, Brighton, United Kingdom.
JAMA Netw Open. 2021 Jul 1;4(7):e2116382. doi: 10.1001/jamanetworkopen.2021.16382.
Wearable physical activity (PA) trackers, such as accelerometers, fitness trackers, and pedometers, are accessible technologies that may encourage increased PA levels in line with current recommendations. However, whether their use is associated with improvements in PA levels in participants who experience 1 or more cardiometabolic conditions, such as diabetes, prediabetes, obesity, and cardiovascular disease, is unknown.
To assess the association of interventions using wearable PA trackers (accelerometers, fitness trackers, and pedometers) with PA levels and other health outcomes in adults with cardiometabolic conditions.
For this systematic review and meta-analysis, searches of MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and PsycINFO were performed from January 1, 2000, until December 31, 2020, with no language restriction. A combination of Medical Subject Heading terms and text words of diabetes, obesity, cardiovascular disease, pedometers, accelerometers, and Fitbits were used.
Randomized clinical trials or cluster randomized clinical trials that evaluated the use of wearable PA trackers, such as pedometers, accelerometers, or fitness trackers, were included. Trials were excluded if they assessed the trackers only as measuring tools of PA before and after another intervention, they required participants to be hospitalized, assessors were not blinded to the trackers, or they used a tracker to measure the effect of a pharmacological treatment on PA among individuals.
The study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. A random-effects model was used for the meta-analysis.
The primary outcome was mean difference in PA levels. When the scale was different across studies, standardized mean differences were calculated. Heterogeneity was quantified using the I2 statistic and explored using mixed-effects metaregression.
A total of 38 randomized clinical trials with 4203 participants were eligible in the systematic review; 29 trials evaluated pedometers, and 9 evaluated accelerometers or fitness trackers. Four studies did not provide amenable outcome data, leaving 34 trials (3793 participants) for the meta-analysis. Intervention vs comparator analysis showed a significant association of wearable tracker use with increased PA levels overall (standardized mean difference, 0.72; 95% CI, 0.46-0.97; I2 = 88%; 95% CI, 84.3%-90.8%; P < .001) in studies with short to medium follow-up for median of 15 (range, 12-52) weeks. Multivariable metaregression showed an association between increased PA levels and interventions that involved face-to-face consultations with facilitators (23 studies; β = -0.04; 95% CI, -0.11 to -0.01), included men (23 studies; β = 0.48; 95% CI, 0.01-0.96), and assessed pedometer-based interventions (26 studies; β = 0.20; 95% CI, 0.02-0.32).
In this systematic review and meta-analysis, interventions that combined wearable activity trackers with health professional consultations were associated with significant improvements in PA levels among people with cardiometabolic conditions.
可穿戴式身体活动(PA)追踪器,如加速度计、健身追踪器和计步器,是一种易于使用的技术,可能会鼓励人们达到当前推荐的更高的身体活动水平。然而,对于患有 1 种或多种心血管代谢疾病(如糖尿病、糖尿病前期、肥胖和心血管疾病)的参与者,使用这些设备是否与身体活动水平的提高相关,目前尚不清楚。
评估使用可穿戴式 PA 追踪器(加速度计、健身追踪器和计步器)干预与成年人心血管代谢疾病相关的 PA 水平和其他健康结果的相关性。
在本次系统评价和荟萃分析中,对 MEDLINE、Embase、Cochrane 对照试验中心注册库和 PsycINFO 进行了检索,检索时间为 2000 年 1 月 1 日至 2020 年 12 月 31 日,无语言限制。使用了糖尿病、肥胖、心血管疾病、计步器、加速度计和 Fitbit 的医学主题词和文本词的组合。
纳入了评估使用可穿戴式 PA 追踪器(如计步器、加速度计或健身追踪器)的随机临床试验或群组随机临床试验。如果试验仅将追踪器评估为另一种干预措施前后 PA 的测量工具、需要参与者住院、评估者对追踪器不设盲、或使用追踪器来评估药物治疗对个体 PA 的影响,则将其排除。
本研究遵循系统评价和荟萃分析的首选报告项目(PRISMA)报告准则。荟萃分析采用随机效应模型。
主要结果是 PA 水平的平均差异。当研究之间的量表不同时,计算了标准化均数差。使用 I2 统计量来量化异质性,并使用混合效应荟萃回归进行探索。
共纳入 38 项随机临床试验,共 4203 名参与者,符合系统评价标准;29 项试验评估了计步器,9 项试验评估了加速度计或健身追踪器。有 4 项研究未提供适宜的结局数据,因此有 34 项研究(3793 名参与者)进行了荟萃分析。干预与对照分析显示,在随访时间为 15 周(范围 12-52 周)的短期至中期研究中,可穿戴追踪器的使用与 PA 水平的显著增加具有相关性(标准化均数差,0.72;95%CI,0.46-0.97;I2=88%;95%CI,84.3%-90.8%;P<0.001)。多变量荟萃回归显示,PA 水平的增加与包括面对面咨询的干预措施(23 项研究;β=-0.04;95%CI,-0.11 至-0.01)、包括男性(23 项研究;β=0.48;95%CI,0.01-0.96)和评估基于计步器的干预措施(26 项研究;β=0.20;95%CI,0.02-0.32)之间存在关联。
在本次系统评价和荟萃分析中,将可穿戴活动追踪器与健康专业人员咨询相结合的干预措施与心血管代谢疾病患者的 PA 水平显著提高相关。